Replies to post #441 on Fate Therapeutics Inc (FATE)

[NY1972]

Did FATE CEO say that? ?d T cells can activate DC and macrophages.
Cytokine Production: ?d T cells produce significant amounts of cytokines like IFN-? and TNF-a, which enhance anti-tumor immunity by promoting other immune cells’ activation and cytotoxicity against tumors.

[NY1972]

That is the role model for FT825?
Chemokine Receptor Expression: ?d T cells express a range of chemokine receptors, such as CCR5, CCR6, and CXCR3, which can respond to chemokine gradients created by tumor cells and stromal cells. This chemokine-guided migration helps ?d T cells home in on tumor sites and penetrate the solid tumor mass.

[NY1972]

aßT cells according to
Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY

iPSC-derived aßT, NK, and iNKT cells are currently being tested in phase I clinical trials. The ability to perform (multiplexed) gene editing at the iPSC level and subsequent differentiation into effector populations not only expands the arsenal of ACT but allows for development of ACT utilizing cell types which cannot be efficiently obtained from peripheral blood or engineered and expanded in vitro.

https://www.sciencedirect.com/science/article/abs/pii/S0301472X24005137